Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Investor Presentation (April 2026)
15 slides from Xbrane Biopharma AB's investor presentation, April 2026
Slide 1: Company Presentation
STO: XBRANE April 2026 Company Presentation 1
Slide 2: Important information
Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in
Slide 3: Biosimilars are follow-on products to biologics, launched post patent expiry
Biosimilars are follow-on products to biologics, launched post patent expiry Pharmaceuticals Small Molecules Biologics → 60% of global market, 1-3% p.a. growth1 → 40% of global market, 10-15% p.a. growth2 → Produced via chemical synthesis → Produced via recombinant DNA technology → Followed on by id
Slide 4: Xbrane has a derisked late-stage biosimilar portfolio set to generate profitability
Xbrane has a derisked late-stage biosimilar portfolio set to generate profitability Biosimilar candidate Ximluci® (ex-US) Lucamzi (US) Xdivane Reference product Therapeutic area Ophthalmology Oncology Dec 2028 (US) Patent expiry 2022 (EU) 2020 (US) June 2030 (EU) Development phase Commercial (Europe
Slide 5: Ximluci launched in 24 countries by partner STADA. Xbrane get 50% of profit
Ximluci® launched in 24 countries by partner STADA. Xbrane get 50% of profit Ximluci® launched by STADA in 24 countries Co-Development & Commercialization Partnership with STADA Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally → Global generics and
Slide 6: Ximluci addressable market in Europe is €5 billion
Ximluci® addressable market in Europe is €5 billion Europe retinal anti VEGF: EUR 5 billion market Commentary → Europe retinal anti VEGF market at approx. €5 billion in € 5 billion 2025 with approx. 7 billion units (excl off label Avastin) 100% shipped Avastin (off-label) → Volume growth of 7% p.a.
Slide 7: Ximluci has captured 8% ranibizumab volume market share in Europe
Ximluci® has captured 8% ranibizumab volume market share in Europe Profit split to Xbrane and growth in vials sold by STADA Commentary → Volume constant Q4 2025 vs. Q3 2025. 140.0 100% → Ximluci® share of ranibizumab market across 120.0 113.7 115.7 114.9 115.8 launched countries in Europe was 8% by
Slide 8: Lucamzi addressable market in the US €9 billion
Lucamzi addressable market in the US €9 billion US retinal anti VEGF: EUR 9 billion market Commentary → Lucentis biosimilars covered under Medicare Part B with 20% patient co-payment € 9 billion 100% Avastin (off-label) → Reimbursement based on ASP* + 6-8% of originator ASP 80% Vabysmo → Dynamic whi
Slide 9: Lucamzi - BLA re-submission planned for April/May 2026
Lucamzi - BLA re-submission planned for April/May 2026 Xbrane & STADA partner with Valorum US Commercialization Partnership Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, → Biosimilar commercialization marketing and commercial efforts in th
Slide 10: Xdivane is one out of five nivolumab biosimilars in clinic
Xdivane is one out of five nivolumab biosimilars in clinic targeting $14b of expected originator sales Opdivo® expected to generate net-sales of $14b globally in 2028 Landscape & Commentary → Opdivo is an immuno-oncology drug (PD1 inhibitor) used in treatment of several cancers including melanoma an
Slide 11: Xdivane is partnered with Intas/Accord with a 30% market share in oncology injectables in Europe
Xdivane is partnered with Intas/Accord with a 30% market share in oncology injectables in Europe Partnership with Intas Global License & Co-Development Agreement Exclusive agreement with Intas signed in 2024. Intas will finance and oversee clinical and regulatory development activities as well as gl
Slide 12: Xdivane clinical trial initiated and program on track towards day 1 launch
Xdivane clinical trial initiated and program on track towards day 1 launch 2024 2025 2026 2027 2028 2029 2030 Commercialization Milestone payment to Milestone payment to Xbrane Xbrane LoE US LoE Europe Production of clinical material Pivotal clinical trial MAA / BLA → Successful scale-up to → Single
Slide 13: Xdivane could generate SEK 1 billion in annual profit sharing
Xdivane could generate SEK 1 billion in annual profit sharing, assuming historic oncology biosimilar penetration and price patterns US biosimilar volume market share vs. reference product Commentary → Oncology biosimilars have been well received with average penetration of 75% at year 3 post launch
Slide 14: Xbrane on path towards full year profitability with stabilized balance sheet
Xbrane on path towards full year profitability with stabilized balance sheet Historical Revenue Split and P&L Commentary → Ximluci product sales and profit sharing recognized upon P&L Overview (SEK, million) 2023A 2024A 2025A shipment of product to Stada (hence variability) License revenues 28.4 132
Slide 15: Investment highlights
Investment highlights Profitable • Ximluci® Europe/MENA income generation expected to cover fixed cost Ximluci ex. US base post ongoing production cost reduction measures base business • Further potential to increase market share • XdivaneTM on timeline towards US approval Q4 2028 and subsequent SEK
Xbrane Biopharma — Investor Presentation (April 2026) on 6ix